Merck's cervical cancer vaccine on sale in Europe

|

Reuters reports that Merck's Gardasil is on sale now.

Uptake of .. vaccines will depend crucially on government recommendations for their use and funding.

The manufacturers received a boost earlier this month when the influential Lancet medical journal called for routine vaccination of all adolescent girls in European Union countries.

This recommendation was also released earlier this month - EU should make cervical cancer vaccine mandatory for young girls.

Noticing that this vaccine "was launched in Britain and Ireland on Tuesday in the latest phase of an unusually rapid rollout for the new product", I can only hope that this vaccine won't get widely accepted and made obligatory without thourough and careful testing.

The way pharmaceutical corporations are securing their profits is amazing. Creating a vaccine, rapidly rolling it out, having respectful journals to call on massive and obligatory vaccination.
Well done. I just hope that EU goverments won't fall for this easily.

Read the article below

LONDON, Oct 17 (Reuters) - Merck & Co Inc's Gardasil, the first vaccine to prevent cervical cancer, was launched in Britain and Ireland on Tuesday in the latest phase of an unusually rapid rollout for the new product.

Sanofi Pasteur MSD, the joint venture between Merck and Sanofi-Aventis which is responsible for European sales, said it had also launched recently in Germany, Austria, Finland and Sweden.

Viewed by analysts as a potential multibillion-dollar-a-year seller, Gardasil is a new kind of vaccine that prevents cervical cancer by protecting against the sexually transmitted human papilloma virus (HPV) that can trigger the disease.

It was given European regulatory approval last month and will be sold in Europe for an ex-factory price of between 300 and 360 euros ($375-450) for a course of three doses.

That translates into a consumer price of 450 to 600 euros, with the price varying due to country-specific factors, such as wholesaler and pharmacy mark-ups.

Sanofi Pasteur MSD aims to have Gardasil on the market in most European countries by the end of the year, though it will not be available in Spain, Italy and Greece until 2007.

It has already been launched in several countries outside Europe, including the United States, where it has been recommended by experts for use in girls as young as nine and young women up to age 26.

GlaxoSmithKline Plc has a rival anti-HPV product called Cervarix waiting in the wings.

Uptake of both vaccines will depend crucially on government recommendations for their use and funding.

The manufacturers received a boost earlier this month when the influential Lancet medical journal called for routine vaccination of all adolescent girls in European Union countries.

Cervical cancer is one of the most common cancers in women. Each year 470,000 women are diagnosed with the disease and 230,000 die. Most of the deaths are in the developing world.

The Lancet said there was growing support for vaccinating both girls and boys against the sexually transmitted virus but added more data from clinical trials in boys was needed.

source

Info

Previous entry: Partial-match Cell Transplants For Children With Most Resistant Leukemia

Next entry: Breast cancer screenings attacked

Find recent content on the main index or look in the archives to find all content.